Other Issues

Current good manufacturing practices establish uniform standards to ensure quality throughout the manufacturing, packaging, labeling, and holding of OTC medicines and dietary supplement products.

CHPA supports the regulatory authorities governing dietary supplement manufacturing, labeling, and marketing and works to ensure the availability of safe dietary supplements.

CHPA opposes mandatory manufacturer-funded drug take-back programs as they threaten the affordability of OTC medications that consumers rely on as the first line of defense against common ailments.

CHPA encourages state and local lawmakers to refrain from creating new legislation addressing green chemistry in pharmaceuticals, and instead rely on the rigorous guidelines and standards already implemented at the federal level by agencies like the FDA.

The Dietary Supplements Access Act of 2023 is bipartisan legislation intended to give American consumers increased flexibility to best determine how to use their pre-tax dollars to stay healthy.

Though rising PFAS levels prompt important health questions that must be monitored, restrictions should remain grounded in conclusive toxicology to avoid reactionary bans on safe modern alternatives — as inconsistent standards across 50 individual states would only stifle healthcare advancement.

Policymakers should encourage – and empower – individuals to take responsibility for their oral health by supporting daily oral health self-care policies that make beneficial oral care products more accessible.

While VOCs can have environmental impacts in aggregate, existing alternatives don’t always provide the consistent therapeutic results needed for OTC products relied upon by millions for. As such, any legislation aimed at further restricting pharmaceutical VOCs must carefully weigh potential unintended consequences on public health.

If you have a flexible spending arrangement (FSA) or health savings account (HSA) you can now use these pre-tax savings for purchasing over-the-counter medicines.